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The Effect of Having an Affected Parent or Sibling on
Invasive and In Situ Skin Cancer Risk in Sweden
Shehnaz K. Hussain1,2, Jan Sundquist3,4 and Kari Hemminki1,5
Studies suggest that skin cancer aggregates within families; however, the risk of skin cancer associated with
having an affected sibling or parent by subtype, tumor site, and age at diagnosis has not been established. The
2006 update of the Swedish Family-Cancer Database was used to calculate standardized incidence ratios (SIRs),
representing the ratio of cancer risk among individuals with affected parents or siblings to the general
population. Risk of invasive squamous cell skin cancer for individuals with an affected sibling or parent was
increased between two- and three-fold compared with that in the general population. For in situ skin tumors,
increased SIRs of 1.95–4.30 for squamous cell, Bowen’s disease, and actinic keratosis were observed for
individuals with affected siblings or parents, and SIRs were generally higher for tumors at sun-exposed versus
covered sites. Finally, SIRs for in situ and invasive squamous cell skin cancer increased by increasing number of
parental tumors (Pp0.01). In conclusion, having an affected sibling or parent was associated with an increased
risk of skin cancer of varied subtypes compared with that in the general population, and for some subtypes,
these familial risks were increased for tumors at sun-exposed sites or by an increasing number of parental
tumors.
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INTRODUCTION
Non-melanoma skin cancer (NMSC) incidence has nearly
tripled over the last 25 years in Sweden, and the increasing
incidence in recent years shows no signs of leveling off (Center
For Epidemiology, 2006). Although NMSC is generally not fatal,
center for treatment can be potentially disfiguring. Furthermore,
the large number of affected individuals poses a great burden to
the health-care system (Housman et al., 2003). Thus, identifica-
tion of individuals at high risk of NMSC may reduce the
personal and societal burden of these cancers.
Squamous cell skin cancer (SCSC) is the main histological
subtype of invasive NMSC, and cumulative exposure to UV
radiation is the most established risk factor for invasive SCSC
(Preston and Stern, 1992). Other risk factors for invasive SCSC
include fair skin (English et al., 1998b), arsenic exposure (Yu
et al., 2006), immunosuppression (Karagas et al., 2001;
Sorensen et al., 2004), cutaneous viral infections (Harwood
et al., 2000), and chronic diseases (Jensen et al., 2008).
Invasive skin cancers with mixed squamous cell and basal
cell components are comparatively much less common, have
a poorly characterized etiology, and have an aggressive
nature, which is underscored by their propensity to recur and
metastasize (Martin et al., 2000; Costantino et al., 2006).
Bowen’s disease and actinic keratosis are in situ skin tumors.
Bowen’s disease is regarded as a true precursor lesion to
invasive SCSC, yet only between 5 and 20% of actinic
keratoses are presumed to have the potential to progress to
invasive SCSC (Marks et al., 1988; Quaedvlieg et al., 2006).
Besides sun exposure, risk factors for these in situ tumors are
not well characterized (Butani et al., 2005).
Several familial syndromes predispose to SCSC and other
NMSC, which suggests that inherited genetic factors are
involved in their etiology (Tsao, 2000; Somoano et al., 2005).
However, whether there is genetic heterogeneity by histologi-
cal subtype, tumor behavior (in situ versus invasive), or
anatomical tumor site has yet to be determined. The majority
of national cancer registries do not capture incidence data for
either invasive or in situ NMSC, which has precluded detailed
genetic epidemiology studies of these skin tumors. With the
exception of basal cell cancer, Sweden has captured data on
NMSC since 1958, and the Swedish Family-Cancer Database,
which includes these data, has been used to examine familial
aggregation of SCSC earlier. This earlier study reported a 2.7-
fold increased invasive and 2.4-fold increased in situ SCSC risk
in individuals with an affected parent (Hemminki et al., 2003a).
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A recent update to the Family-Cancer Database has greatly
increased the follow-up time from the earlier database by six
additional years, and has captured nearly twice as many
invasive and in situ SCSC diagnoses. Thus, this updated
database permits a more detailed examination of risks of
SCSC and other NMSC associated with having affected family
members compared with that in the earlier study (Hemminki
et al., 2003a). The intent of this investigation is to confirm
and extend results from the earlier study by examining parent
and sibling effects on the risk of invasive SCSC, invasive
mixed squamous/basal cell cancer, and in situ skin tumors.
We report for the first time the risk of SCSC, mixed squamous/
basal cell cancer, Bowen’s disease, and actinic keratosis
associated with having an affected sibling, and the risk
associated with having an affected parent or sibling by
anatomical tumor site. The significance of this study is that it
greatly extends our knowledge regarding risk factors for SCSC
and other NMSC; such information is valuable for physicians
and genetic counselors for risk assessment, and primary and
secondary prevention strategies for their patients, and
furthermore may be incorporated into national guidelines
and recommendation for sun protection and screening.
RESULTS
For this study, 214,856,618 person-years of follow-up were
available for analysis as part of the Family-Cancer Database
(version VII, MigMed2). A total of 3,867 invasive and 5,314
in situ primary SCSC or mixed squamous/basal cancers were
identified. The majority of these tumors occurred as single
events in a family, whereas 156 familial pairs (23 sibling pairs
and 133 parent–offspring pairs) and 3 parent–offspring–sibling
trios were affected by invasive skin cancer, and 332 familial
pairs (49 sibling pairs and 283 parent–offspring pairs) and 7
parent–offspring–sibling trios were affected by in situ skin
tumors.
For individuals with family members affected with skin
cancer of ‘‘any histology’’ (PAD 146 and PAD 126 for
invasive cancers or PAD 144, SNOMED 80812, and
SNOMED 72850 for in situ tumors), having an affected
sibling (sibling proband) or parent (parent proband) was
associated with a two- to three-fold increased risk of invasive
and in situ (according to PAD) SCSC, compared with that in
the general population (Table 1). An increased risk of mixed
squamous/basal cell cancer was associated with having an
affected sibling (standardized incidence ratios, (SIR)¼3.99),
although this was not statistically significant. Bowen’s disease
and actinic keratosis were the most common in situ NMSC
reported between 1993 and 2004 using the SNOMED (ICD-
O-2/ICD Systematized Nomenclature of Medicine) histo-
pathological classification system. Compared with the gen-
eral population, individuals with an affected sibling or parent
were at increased risk of Bowen’s disease, which was similar
in strength to the increased risk of in situ SCSC according to
the PAD histopathological classification for the entire study
period (1958–2004). Individuals with an affected sibling had
a much greater risk of actinic keratosis (SIR¼4.30). SIRs were
generally of the same direction and similar magnitude when
individuals were diagnosed with the same histological
subtype as their affected family member (‘‘concordant
histology’’).
Invasive and in situ SCSC risk and Bowen’s disease at
either a sun-exposed or a covered anatomical site were
significantly increased among individuals with an affected
parent compared with those in the general population, and
the SIRs were higher for sun-exposed compared with those
for covered sites, although the difference was not statistically
significant (Table 2). Actinic keratosis risk at sun-exposed, but
not covered, sites was increased among individuals with an
affected parent. Having an affected sibling was associated
with an increased risk of invasive mixed squamous/basal cell
Table 1. Invasive and in situ histological-specific skin cancer risk according to skin cancer in sibling and parent
probands
Sibling proband Parent proband
Any histology1 Concordant histology Any histology Concordant histology
Invasive and in situ
histological-specific skin cancer N2 SIR3 95% CI4 N SIR 95% CI N SIR 95% CI N SIR 95% CI
Invasive
Squamous cell (PAD 146) 23 2.85 1.27 6.05 19 3.10 1.87 4.86 127 2.25 1.88 2.70 113 2.34 1.93 2.82
Mixed squamous/basal cell (PAD 126) 3 3.99 0.75 11.80 2 5.32 1.00 15.80 9 1.64 0.74 3.13 5 1.06 0.33 2.48
In situ
Squamous cell (PAD 144) 56 2.60 1.96 3.37 53 2.58 1.93 3.37 290 2.17 1.93 2.43 281 2.17 1.92 2.44
Bowen’s disease5 (SNOMED 80812) 36 2.41 1.68 3.33 9 1.67 0.76 3.18 207 2.20 1.91 2.53 64 3.16 2.44 4.04
Actinic keratosis5 (SNOMED 72850) 8 4.30 1.84 8.51 0 21 1.95 1.21 2.99 1 1.34 0.00 7.70
1Probands were affected with either PAD 146 or PAD 126 for calculation of the SIRs for invasive carcinoma, and probands were affected with PAD 144,
SNOMED 80812, or SNOMED 72850 for calculation of the SIRs for in situ carcinoma.
2N, number of observed parent or sibling proband cases.
3SIR, standardized incidence ratios were adjusted for age, sex, time period, geographical residence, and socioeconomic status.
4CI, confidence interval.
5SIR calculations were based on a restricted follow-up period (1993–2004).
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cancer, in situ SCSC, Bowen’s disease, and actinic keratosis
only at sun-exposed sites, whereas invasive SCSC risk was
increased at sun-exposed and covered sites. A small number
of individuals with multifocal skin cancers (2 in situ cases
with affected siblings, 1 invasive case with an affected parent,
and 3 in situ cases with affected parents) and skin cancers
diagnosed in unspecified locations (3 in situ cases with
affected siblings, 5 invasive cases with affected parents, and
18 in situ cases with affected parents) were not included in
the results presented in Table 2.
Invasive SCSC risk associated with having an affected
parent was highest among individuals diagnosed at age p39
years, and in situ SCSC risk was highest in the 40–49 age
group, although there were no significant trends for increas-
ing SIRs by decreasing age at diagnosis (Table 3). A
statistically significant linear trend for increasing invasive
and in situ SCSC risk associated with having an affected
parent by increasing number of parental tumors was observed
(Table 4). Thirty-four additional parental cancer sites were
examined for their association with skin cancer risk in their
offspring (data not tabulated). Individuals with parents
affected with melanoma were at an increased risk of invasive
SCSC (N¼ 46, SIR¼1.67, 95% confidence interval
(CI)¼ 1.22–2.22) and Bowen’s disease (N¼ 27, SIR¼1.66,
95% CI¼1.10–2.43), and individuals with parents affected
with liver cancer were at an increased risk of invasive mixed
squamous/basal cell cancer (N¼ 10, SIR¼2.21, 95%
CI¼1.05–4.08), compared with the general population.
DISCUSSION
This study shows that individuals with a sibling or parent
affected with skin cancer have an increased risk of skin
cancer of varied subtypes compared with the general
population, and for some subtypes, these risks are increased
for tumors at sun-exposed sites or by an increasing number of
parental tumors. The main strengths of this study include
nationwide coverage, complete ascertainment of incident
cancers, reconstruction of nuclear families through data
linkage removing any possibility of recall bias, and precision
of the SIR estimates due to a long duration of follow-up and
high number of cancer diagnoses for common histological
subtypes (that is, invasive and in situ SCSC). This investigation
is somewhat limited in its ability to comprehensively assess
familial risks for rare histological subtypes (that is mixed
squamous/basal cell cancers); nonetheless, this study is the
first of its kind and will certainly help to inform future studies.
Another limitation of this study is a lack of person-level data
on lifetime sun exposure, and the use of an anatomical tumor
site as a surrogate for the relationship between sun exposure
and cancer risk. Finally, familial risks reflect etiological
Table 2. Invasive and in situ histological-specific skin cancer risk by anatomical tumor location according to skin
cancer in sibling and parent probands
Sibling proband Parent proband
Anatomical location
of tumor1
Invasive and in situ
histological-specific skin cancer N2 SIR3 95% CI4 P-value5 N SIR 95% CI P-value
Sun-exposed site6 Invasive
Squamous cell (PAD 146) 16 2.64 1.51 4.30 101 2.44 1.98 2.96
Mixed squamous/basal cell (PAD 126) 3 5.42 1.02 16.1 7 1.70 0.67 3.52
In situ
Squamous cell (PAD 144) 41 2.91 2.08 3.95 192 2.23 1.93 2.57
Bowen’s disease7 (PAD 80812) 29 3.01 2.02 4.33 132 2.21 1.85 2.62
Actinic keratosis7 (PAD 72850) 8 4.99 2.13 9.88 19 2.05 1.23 3.21
Covered site Invasive
Squamous cell (PAD 146) 7 4.11 1.63 8.52 0.33 22 1.75 1.09 2.65 0.17
Mixed squamous/basal cell (PAD 126) 0 1 1.01 o0.01 5.81 0.62
In situ
Squamous cell (PAD 144) 10 1.71 0.81 3.15 0.13 77 2.03 1.60 2.54 0.49
Bowen’s disease7 (PAD 80812) 6 1.43 0.51 3.13 0.09 65 2.19 1.69 2.79 0.95
Actinic keratosis7 (PAD 72850) 0 1 0.98 o0.01 5.65 0.42
1Does not include multifocal or site-unspecified tumors.
2N, number of observed parent or sibling proband cases.
3SIR, standardized incidence ratios were adjusted for age, sex, time period, geographical residence, and socioeconomic status.
4CI, confidence interval.
5One degree of freedom w2 test for homogeneity of SIRs for sun-exposed and covered sites.
6Sun-exposed sites were defined as tumors occurring on the head, neck, arms, and legs (for women only). All other tumor sites were considered covered.
7SIR calculations were based on a restricted follow-up period (1993–2004).
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contributions of shared environment and inherited genetics;
thus, we do not know the specific contribution of each to the
SIRs observed in this study.
Although there is a scarcity of prior literature on familial
aggregation of skin cancer, our results were largely consistent
with earlier reports from the Swedish Family-Cancer Database
(Hemminki and Dong, 2000; Hemminki et al., 2003a, b),
although a few notable differences were also apparent. The
SIRs for invasive and in situ SCSC risk associated with having
an affected parent were slightly lower in our study compared
with those in earlier reports. One explanation for this is that
the individuals included in the earlier cohort were truncated
at the age of 66 years compared with that of 72 years in this
investigation. Familial cancers tend to manifest at younger
ages compared with sporadic cancers; thus, in this study,
sporadic cases may comprise a greater proportion of the total
number of cases, resulting in a dilution of the effect of
aggregation due to shared genetics compared with that in the
earlier cohort (Marra and Boland, 1995; Tsao, 2000; Risch,
2001; de Sanjose et al., 2003). A second notable difference is
that the prior study reported no appreciable differences in the
SIRs by an anatomical tumor site. In this study, most SIRs for
both invasive and in situ cancers were higher for sun-exposed
tumor sites compared with covered sites, particularly those
associated with affected parents, although the differences
were not statistically significant. This may also be attributed to
the fact that this study captured a larger proportion of older
cancer cases who are more likely to have a larger environ-
mental component to their cancer risk (that is, sun exposure)
compared with the earlier cohort.
The observation of slightly higher SIRs associated with
having an affected sibling compared with an affected parent
has several possible explanations. First, studies have shown
that sun exposure during childhood is an important risk factor
Table 3. Invasive and in situ squamous cell skin cancer risk by age of diagnosis according to squamous cell skin
cancer in parent probands
Invasive (PAD 146) In situ (PAD 144)
Offspring age at diagnosis
(in years) N1 SIR2 95% CI3 N SIR 95% CI
p39 7 3.12 1.24 6.47 8 1.29 0.55 2.56
40–49 17 2.04 1.18 3.27 53 2.46 1.84 3.21
50–59 51 2.21 1.64 2.91 130 2.28 1.90 2.71
X60 52 2.29 1.71 3.00 99 2.03 1.65 2.47
P-value4 0.88 0.89
1N, number of observed parent proband cases.
2SIR, standardized incidence ratios were adjusted for age, sex, time period, geographical residence, and socioeconomic status.
3CI, confidence interval.
4One degree of freedom w2 test for trend.
Table 4. Invasive and in situ squamous cell skin cancer risk according to single or multiple squamous cell skin
tumors in parent probands
Invasive (PAD 146) In situ (PAD 144)
Skin tumor(s) in parent proband
(PAD 146 and PAD 144) N1 SIR2 95% CI3 N SIR 95% CI
1 in situ 82 1.54 1.22 1.91 199 1.98 1.71 2.27
1 Invasive 89 2.06 1.65 2.53 153 1.88 1.60 2.21
2 In situ 15 2.09 1.17 3.46 34 2.48 1.72 3.47
2 Invasive 6 2.19 0.79 4.80 15 2.91 1.63 4.82
1 Invasive and 1 in situ 16 2.75 1.57 4.47 34 3.04 2.11 4.26
1 Invasive and 2 in situ 9 4.21 1.91 8.02 11 2.70 1.34 4.85
2 Invasive and 1 in situ 5 4.41 1.39 10.38 7 3.21 1.27 6.65
2 Invasive and 2 in situ 4 4.88 1.27 12.61 5 3.07 0.97 7.22
P-value4 o0.01 o0.01
1N, number of observed parent proband cases.
2SIR, standardized incidence ratios were adjusted for age, sex, time period, geographical residence, and socioeconomic status.
3CI, confidence interval.
4One degree of freedom w2 test for trend.
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for SCSC in adulthood (English et al., 1998a), and SIRs for
siblings are likely to be influenced by shared levels of
childhood sun exposure, whereas parents and their offspring
may have different levels of exposure due to differences in
lifestyle, residence, etc. Inherited genetic susceptibility
provides another potential explanation. For a given genetic
locus, offspring inherit only one allele from each parent,
whereas siblings can share up to two alleles. Recessive
genetic effects would therefore be most apparent among
siblings. Xeroderma pigmentosa is an extreme example of a
rare autosomal-recessive genetic disorder predisposing to
SCSC, which is characterized by defects in DNA repair and
DNA helicase genes (Tsao, 2000); however, population-
based studies have yet to identify susceptibility loci for SCSC
in non-xeroderma pigmentosa syndrome families.
Although there was no significant trend for increasing
SCSC risk associated with having an affected parent by
decreasing age of diagnosis, invasive SCSC risk was highest in
the youngest age group (p39 years), and in situ SCSC risk
was highest in the second youngest age group (40–49 years)
and decreased in each subsequent age group, which provides
some additional support for the role of shared genetics in the
etiology SCSC. Furthermore, the dramatic increase of SIRs
associated with having an affected parent by increasing
number of parental tumors also suggests that there may be a
genetic predisposition to invasive and in situ SCSC. In
addition, in terms of clinical value, these data suggest that
the number of parental tumors may be a more important
determinant of SCSC risk than affection status of the parent
(that is, affected/not affected).
The increased risk of invasive SCSC and Bowen’s disease
conferred by having a parent with melanoma has been
observed earlier and is likely due to sun exposure or skin type
(Hemminki et al., 2003a). The association between parental
liver cancer and increased mixed squamous/basal cell cancer
risk is a new observation with no obvious explanation.
This study extends our current understanding of the
familial risks of certain subtypes of skin cancer, and supports
the use of family history for identifying individuals at high risk
of these cancers. Ultimately, such information will help
clinicians to individualize cancer prevention strategies and
screening regimens for their patients. Furthermore, future
studies using molecular genetic techniques may help to
identify inherited genetic factors that are responsible for some
of the observed aggregation of skin cancer, which may be
developed as chemopreventative or therapeutic targets in the
future.
MATERIALS AND METHODS
Swedish Family-Cancer Database
This study used the 2006 update of the Swedish Family-Cancer
Database (version VII, MigMed2), which was created by Statistics
Sweden by linking individual-level census information, death
notifications, and the Administrative Family Register to the Swedish
Cancer Registry using a unique national identification number
(Hemminki et al., 2001a). To preserve the anonymity of the
population, the Family-Cancer Database does not contain these
national identification codes. Instead, technical identification
numbers assigned to each individual by Statistics Sweden are
included in the database. Statistics Sweden and the ethical board of
the Karolinska Institute have approved the study. More than 11
million individuals, of whom 7.4 million aged 0–72 years, who were
born in Sweden between 1932 and 2004, and their biological
parents were included in the Family-Cancer Database. In total, more
than one million primary cancers diagnosed between 1961 and
2004 were captured by the database.
Family history ascertainment
In the Administrative Family Register, children born in Sweden since
1932 were registered with their biological parents (those pleading
parenthood at birth) as families, by matching their unique national
identification numbers. In this study, only full biological siblings
were considered to be ‘‘siblings,’’ which was determined by exact
matching of both maternal and paternal identification numbers for
each child of a sibship. A sibship of size 42 was handled using the
multiple counting method, wherein all possible pairs of siblings were
considered. This method provides an unbiased estimate of the risk to
the siblings of a specified affected individual, regardless of family
size distribution (Hemminki et al., 2001b).
Cancer ascertainment
Invasive and in situ skin cancers were identified by the first three digits
of the 7th revision of the International Classification of Diseases (ICD-
7), code 191. Broad histopathological classifications based on WHO/
HS/CANC/24.1 coding (World Health Organization, 1956) was used
to identify and differentiate invasive SCSC (code 146), invasive mixed
squamous/basal cell cancer (code 126), and in situ SCSC (code 144).
This histological classification was available for tumors diagnosed
throughout the study period, and is referred to as ‘PAD’ coding. A new
system of histopathological classification, SNOMED (http://www.sno-
med.org), was implemented in 1993. This ‘SNOMED’ coding was
used in this study to identify and differentiate between Bowen’s
disease (codes 80812 and 80702) and actinic keratosis (code 72850),
diagnosed between 1993 and 2004. Nearly 100% of all skin cancers
diagnosed during the study period were histologically verified
on account of compulsory nationwide registration by clinicians,
pathologists, and cytologists (Center for Epidemiology, 2006).
Statistical analyses
The SIR was calculated as the ratio of observed to expected number of
skin cancer cases, according to observed cancer in either a sibling or
parental proband. The expected numbers were computed from
primary skin cancer incidence rates in the database standardized for
age (five categories: p29, 30–39, 40–40, 50–59, and X60 years), sex,
time period (three categories: 1961–1979, 1980–1989, and
1990–2004), geographical residence (five categories: Stockholm area,
Go¨teborg-Malmo¨, Go¨taland, Svealand, and Norrland), and socio-
economic status (six categories: agriculture, worker, blue collar,
professional, private, and other) (Esteve, 1994). Person-years at risk
were accumulated beginning at birth or the study start date of 1 January
1958, whichever came latest, and ending at the first occurrence of a
diagnosis of any primary invasive or in situ cancer, death, emigration,
or the study end date of 31 December 2004. The 95% CI for the SIR
was calculated assuming a Poisson distribution (Esteve, 1994). The
variances of the SIRs for cancer risks associated with having an affected
sibling were inflated due to the fact that families with multiple-affected
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siblings were ascertained multiple times. The 95% CI for the SIRs were
corrected for this inflation by halving the observed and expected
numbers of cancers, as described earlier (Goldgar et al., 1994). SIRs
were initially calculated separately for men and women, and later
combined and adjusted for sex (as presented) when no substantial
differences in the SIRs by sex were apparent.
Histological-specific SIRs were calculated for individuals with an
affected parent or sibling with a skin cancer of the same histology
(concordant histology) and of any histology (PAD 146 and PAD 126
for invasive cancer; and PAD144, SNOMED 80812, and SNOMED
72850 for in situ cancer). SIRs were also stratified by the location of
the skin tumor, which was provided by the fourth digit of the ICD-7
code. For this study, sun-exposed sites were defined as tumors
occurring on the head, neck, and arms. For women, legs were also
considered sun-exposed. All other tumor sites were considered
covered. In addition, SIRs for invasive and in situ SCSC associated
with having an affected parent were stratified by age at diagnosis and
the number of parental tumors. The w2 statistic was calculated and
the associated P-value was determined to (1) test for homogeneity of
the SIRs for sun-exposed versus covered sites, and (2) test for a linear
trend for increasing SIRs by decreasing offspring age at diagnosis and
increasing number of parental tumors (Breslow and Day, 1987).
P-values p0.05 were considered significant. Finally, SIRs for
invasive and in situ SCSC and mixed squamous/basal cell cancers
were calculated for individuals with a parental history of cancer at
the 34 most common sites in the database. The first three digits of the
ICD-7 code for the cancer sites presented in the Results section
include 155 and 156 for liver cancer, and 190 for melanoma.
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